The Bull and Bear Case for Anadys (ANDS, $1.00)Friday, June 24, 2011 · 1:56 pm |
|
Thoughts on Recent Poor Stock Performance (ANDS, $1.09)Saturday, June 4, 2011 · 9:31 am |
|
Investment Negatives and Positives (ANDS, $2.06)Saturday, June 4, 2011 · 9:24 am |
|
Initial Meeting with Anadys' CEO Steve Worland (ANDS, $2.33)Saturday, June 4, 2011 · 9:16 am |
|
Update on Anadys' Lead Drug, ANA-598 for Hepatitis C (ANDS, $2.06)Saturday, June 4, 2011 · 9:03 am |
|
Onsite Meeting with Anadys' CEO Steve Worland (ANDS, $1.77)Wednesday, May 4, 2011 · 9:10 am |
|
|
There are 6 reports on file. |
